Nexus Pharmaceuticals announces approval of Emerphed injection
“With the approval of our Emerphed Injection, Nexus Pharmaceuticals is looking to streamline the standard of care in the operating room,” said Mariam S. Darsot, Chief Executive Officer
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for centanafadine, an investigational, once-daily extended-release capsule for attention-deficit hyperactivity disorder (ADHD) treatment.
Demand for these products, including Midazolam, Cisatracurium, and Rocuronium, has skyrocketed as a result of the global coronavirus pandemic. “For more than 30 years we have invested in
The trial dubbed CheckMate -743 saw the Opdivo, Yervoy combination delivered a statistically significant and clinically meaningful improvement in overall survival (OS) compared to chemotherapy comprised of pemetrexed
The study is expected to enroll approximately 270 patients across countries with high numbers of diagnosed cases, beginning in May, and will evaluate the impact of ULTOMIRIS, a
“Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly-established relationship with Complete Phytochemical Solutions
Pemazyre is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR). Continued